Granules India’s shares fell nearly 8% after the US FDA issued a warning letter regarding its Gagillapur facility, citing ...

As part of its enforcement activities, the Food and Drug Administration sends warning letters to entities under its jurisdiction. Some letters are not ...

Granules added that manufacturing and distribution of its existing products at the facility will continue unaffected.

The USFDA issued a warning letter to Granules India Ltd's Gagillapur facility after an August 2024 inspection highlighted ...

"On February 26, 2025, the US FDA issued a Warning Letter to Granules' Gagillapur facility based on its inspection conducted ...

The Warning Letter is dated February 26, 2025 and the facility continues to hold an "Official Action Indicated" (OAI) status.

Granules India's Gagillapur facility receives FDA warning letter, impacting product submissions review until resolved, company remains confident in resolution.

The development may temporarily delay the approval of pending product submissions from the site, but existing manufacturing ...

Drug firm Granules India Ltd on Thursday (February 27) announced that the US FDA has issued a Warning Letter for its ...

Next Science (ASX:NXS) shares fell -13% on Tuesday morning trades, to 10cps, after the company revealed it’s received a ...

A federal judge has dismissed a lawsuit filed by a former employee of Olympus, alleging that he was fired for sounding the ...

In this interview, Professor Ted Dinan, Medical Director at Atlantia Clinical Trials, and Asa Waldstein, Principal at ...